AMP945 Shows Efficacy in Model of Lung Fibrosis
Filed with ASX · · 2 pages · English
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- Preliminary Final Report and Annual Report YE 31 March 2022
- Amplia Receives Second Ethics Clearance for Phase 2 Trial
- AMP945 Pre-IND Meeting Outcome
- Quarterly Activities and Cashflow Reports - March 2022 Qtr
- Ethics Clearance Phase 2 Trial - Pancreatic Cancer Patients
Later from Amplia Therapeutics
- Quarterly Activities and Cashflow Reports - June 2022 Qtr
- First Patient Recruited to ACCENT Trial in Pancreatic Cancer
- CEO & Managing Director Presentation to AGM
- Amplia Receives $1.8m R&D Tax Incentive
- CEO Resignation
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics